Marshall Wace’s Actuate Therapeutics ACTU Stock Holding History

Marshall Wace’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-16,114	Closed	-$109K	–	3278
2025 Q1	$109K	Buy	+16,114	New	+$129K	﹤0.01%	2490

Other funds holding ACTU

BCM

BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northwestern University Evanston, Illinois $63.3M AUM 0.76% 1-Year Est. Return

Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return

Marshall Wace's ACTU Position: Q2 2025 in Review

Marshall Wace sold out of Actuate Therapeutics (ACTU) in Q2 2025, closing a stake of 16,114 shares — an estimated $109K sold.

Marshall Wace first reported a position in ACTU in Q1 2025 and held it in 1 quarter. The position peaked at $109K in Q1 2025. 38 funds tracked by Wall St. Rank hold ACTU as of Q2 2025.

Marshall Wace reported no remaining Actuate Therapeutics position as of Q2 2025 after selling out during the quarter.
Marshall Wace sold 16,114 Actuate Therapeutics shares in Q2 2025, an estimated $109K.
Marshall Wace first reported a position in Actuate Therapeutics in Q1 2025 and held it in 1 quarter.
Marshall Wace's Actuate Therapeutics position peaked at $109K in Q1 2025.
38 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2025.

Based on Marshall Wace's 13F filing for Q2 2025, filed 13 Aug 2025.